A Multicenter, Placebo-controlled, Randomized, Double-blind, Parallel-group Comparison Trial to Investigate the Efficacy and Safety of Brexpiprazole Once-weekly (QW) Formulation in Patients With Acute Schizophrenia
Latest Information Update: 17 Mar 2025
At a glance
- Drugs Brexpiprazole (Primary)
- Indications Schizophrenia
- Focus Registrational; Therapeutic Use
- Sponsors Otsuka Pharmaceutical
Most Recent Events
- 23 Jan 2025 Planned End Date changed from 1 May 2025 to 1 Mar 2026.
- 23 Jan 2025 Planned primary completion date changed from 1 Apr 2025 to 1 Feb 2026.
- 20 Sep 2023 Planned number of patients changed from 550 to 450.